Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders
Authors:
- 1 January 2019
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 193, 75-82
Abstract
No abstract availableKeywords
Funding Information
- Statutory Funds of the Polish Academy of Science
- National Science Centre (2012/ 6/06/A/NZ7/00014)
- NCN (2015/17/B/NZ7/02984)
This publication has 113 references indexed in Scilit:
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activityNature Neuroscience, 2012
- Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophreniaPsychopharmacology, 2011
- The size and burden of mental disorders and other disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV SchizophreniaJournal of Clinical Psychopharmacology, 2011
- On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039Psychopharmacology, 2010
- GABAA receptors: Subtypes provide diversity of function and pharmacologyNeuropharmacology, 2009
- Systematic of psychiatric disorders between categorical and dimensional approachesEuropean Archives of Psychiatry and Clinical Neuroscience, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Antidepressant‐like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodentsBritish Journal of Pharmacology, 2006